Analysts Issue Forecasts for Pyxis Oncology FY2027 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – William Blair issued their FY2027 earnings per share estimates for shares of Pyxis Oncology in a report issued on Tuesday, March 18th. William Blair analyst A. Hsieh anticipates that the company will post earnings per share of ($1.27) for the year. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.01. The firm had revenue of $16.15 million during the quarter.

A number of other equities analysts also recently issued reports on PYXS. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Pyxis Oncology in a research note on Wednesday. Royal Bank of Canada restated an “outperform” rating and set a $8.00 target price on shares of Pyxis Oncology in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.20.

Pyxis Oncology Stock Performance

NASDAQ PYXS opened at $1.21 on Thursday. Pyxis Oncology has a one year low of $0.99 and a one year high of $6.18. The company has a market capitalization of $74.52 million, a price-to-earnings ratio of -1.17 and a beta of 1.11. The company’s 50-day simple moving average is $1.33 and its two-hundred day simple moving average is $2.36.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Ridgeback Capital Investments L.P. acquired a new stake in Pyxis Oncology in the fourth quarter valued at approximately $560,000. ProShare Advisors LLC purchased a new stake in shares of Pyxis Oncology during the 4th quarter valued at $26,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Pyxis Oncology in the 4th quarter worth $228,000. Millennium Management LLC grew its stake in Pyxis Oncology by 53.8% during the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock worth $4,650,000 after buying an additional 1,043,228 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its position in Pyxis Oncology by 57.2% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company’s stock valued at $939,000 after buying an additional 219,100 shares in the last quarter. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.